Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.
Journal: Journal of medicinal chemistry
Published: June 29, 2026
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis.
Journal: Respiratory research
Published: May 28, 2025
Reduced activation of pain-related brain regions with lysophosphatidic acid receptor subtype-1 antagonist PIPE-791 in a nonhuman primate model of chronic peripheral neuropathy.
Journal: Neuropharmacology
Published: February 05, 2025
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 31, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy.
Journal: ACS chemical neuroscience
Published: January 24, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis.
Journal: Scientific reports
Published: December 01, 2023
Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.
Journal: ACS medicinal chemistry letters
Published: November 27, 2020
Showing 1-7 of 7
Last Updated: 09/26/2026